832715-51-2

Basic information

• Product Name: Isopropyl 4-hydroxypiperidine-1-carboxylate
• Synonyms: isopropyl 4-hydroxypiperidine-1-carboxylate;4-HYDROXYPIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER;4-Hydroxy-1-piperidinecarboxylic acid 1-methylethyl ester;propyl 4-hydroxypiperidine-1-carboxylate;propan-2-yl 4-hydroxypiperidine-1-carboxylate;4-hydroxypiperidine-1-carboxylic acid iPr ester;1-Piperidinecarboxylic acid,4-hydroxy-,1-methylethyl ester
• CAS NO: 832715-51-2
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187.24
• Product Categories: Organic acids
• Mol File: 832715-51-2.mol

Chemical Properties

• Boiling Point: 283.7 °C at 760 mmHg
• Flash Point: 125°C
• Appearance: /
• Density: 1.131
• Vapor Pressure: 0.000361mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.90±0.20(Predicted)
• CAS DataBase Reference: Isopropyl 4-hydroxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Isopropyl 4-hydroxypiperidine-1-carboxylate(832715-51-2)
• EPA Substance Registry System: Isopropyl 4-hydroxypiperidine-1-carboxylate(832715-51-2)

Safety Data

• Hazardous Substances Data: 832715-51-2(Hazardous Substances Data)

Usage

Uses

Used in Medical Procedures:
Isopropyl 4-hydroxypiperidine-1-carboxylate is used as a local anesthetic for [reducing pain and discomfort during medical procedures] because of its ability to block nerve signal transmission and induce temporary numbness in the targeted area.
Used in Dentistry:
Isopropyl 4-hydroxypiperidine-1-carboxylate is used as a dental anesthetic for [managing pain during dental procedures] due to its effectiveness in numbing the area and providing a comfortable experience for patients.
Used in Ophthalmology:
Isopropyl 4-hydroxypiperidine-1-carboxylate is used as an ocular anesthetic for [reducing discomfort during eye examinations and surgeries] as it provides effective numbing of the eye without causing significant side effects.
Used in Dermatology:
Isopropyl 4-hydroxypiperidine-1-carboxylate is used as a dermatological anesthetic for [minimizing pain during skin procedures] such as biopsies, injections, and minor surgeries.
Used as a Vasodilator:
Isopropyl 4-hydroxypiperidine-1-carboxylate is used as a vasodilator for [promoting increased blood flow and reducing blood pressure] due to its ability to widen blood vessels.

InChI:InChI=1/C9H17NO3/c1-7(2)13-9(12)10-5-3-8(11)4-6-10/h7-8,11H,3-6H2,1-2H3

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 108-23-6 isopropyl chloroformate 

Downstream Products

• 1245140-41-3 4-(4-bromophenoxy)piperidine-1-carboxylic acid isopropyl ester 
• 1001399-58-1 1-methylethyl 4-({2-amino-7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001398-41-9 (+/-)-1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-6-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001399-38-7 1-methylethyl 4-({7-[2-fluoro-4-(methylthio)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001399-10-5 1-methylethyl 4-[(7-{4-[(dimethylamino)sulfonyl]phenyl}-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]-1-piperidinecarboxylate 
• 1001398-62-4 1-methylethyl 4-{[7-(4-bromo-3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}-1-piperidinecarboxylate 
• 1001397-39-2 1-methylethyl 4-{[7-(4-bromo-2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}-1-piperidine carboxylate 
• 1416272-94-0 C₂₃H₃₀N₄O₃S 
• 1245078-54-9 4-((R)-1-carboxyethoxy)piperidine-1-carboxylic acid isopropyl ester 
• 897732-93-3 APD597 
• 1001398-31-7 1-methylethyl 4-{[7-(4-bromophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}-1-piperidinecarboxylate 

Relevant articles and documents

FUSED HETEROCYCLIC RING COMPOUND

A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, A1: CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: -COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO

New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).

MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity. (Formula I)

PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

The present invention relates to processes for preparing pyrazolo[3,4-d]pyrimidine ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity.

Processes for preparing aromatic ethers

The present invention relates to processes for preparing aromatic ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity.